Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors.
about
Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxisComparison of bypassing agents in bleeding reduction in treatment of bleeding episodes in patients with haemophilia and inhibitorsRituximab in the treatment of high responding inhibitors in severe haemophilia A.Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in IranHealth economics of treating haemophilia A with inhibitors.Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors.The emerging role of recombinant activated Factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage.Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors.High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance.Ectopic platelet-delivered factor (F) VIII for the treatment of Hemophilia A: Plasma and platelet FVIII, is it all the same?Bleeders, bleeding rates, and bleeding score.ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective.Strategies for inhibitor treatment and costs in the short and long term: a critical evaluation of recent clinical studies.Comorbidities and inhibitors in adult patients with haemophilia: issues, costs and management strategies.Future characteristics of bypassing agents to improve care of hemophilia inhibitor patients: an economic and health-related quality of life perspective.Physicians' preferences towards coagulation factor concentrates in the treatment of Haemophilia with inhibitors: a discrete choice experiment.Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors.Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment.Cost minimization model for treatment of minor bleeding episodes in inhibitor patients -- methodological issues.A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil.Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment.Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors.Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.Gene therapy in hemophilia A: a cost-effectiveness analysis
P2860
Q26865814-E8B151B6-7A9B-4B79-8CFD-BBC2832C9B82Q28081532-38E4DA8D-7349-4C82-AB6E-4D782021FAABQ34651588-962ED29D-0DF6-4685-AB7F-2486D34A1A82Q35602600-C9AFA3C2-4E78-4CD8-9DFA-F3C6DA669204Q36283841-D70EF7EC-526C-4FD5-8602-86CFFD17B66DQ36291064-7A36CDE9-2F0E-4DBE-9C90-A5191C3E471EQ36349573-1F7DD399-CBEE-40E6-A18B-0B6A02B1696BQ36828144-6BBFAD29-19A9-4AF1-9F45-006F2F8A1598Q37153668-3FF52CD2-1B45-4042-8CA0-D93D8ABE022BQ37366619-EDD8F4DD-C1D6-4C06-932E-0E3ECB5D3B27Q38117731-9C04A7E5-F430-41DB-A3DE-BA4BCA08A523Q38224296-582E845B-E968-47C7-B029-A55A0DD2160EQ38308212-85B3C252-C122-4CC2-9028-120DFE8F962DQ38613927-83640150-A7A8-4460-BEE7-2EC26FA3B550Q39261141-FCE85B34-2108-46BE-BB6E-470F9EF460D1Q39323587-9F4441EC-DE00-4DED-937E-3BF36D382817Q44100628-D4D74953-A730-45F2-AC38-5C540E496167Q45260428-BE35BED6-49C0-4838-8A37-13537A38E018Q45855148-010C82E0-3E24-4140-9170-E37297C195CBQ45871197-153C8CAC-C9F4-41EE-9B1C-E6DAC5FE6478Q45886106-173A9645-3822-42F7-AD86-7F879FA5886BQ45887517-70CF8D9D-43F4-48DB-9CEB-2A9FB46D41EFQ45888243-6FD498F4-1A43-4551-BA76-DDB2278F7E96Q57083979-5E487199-A012-4889-AE9D-57BE370CB109
P2860
Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Economic modelling of differen ...... th high-responding inhibitors.
@ast
Economic modelling of differen ...... th high-responding inhibitors.
@en
type
label
Economic modelling of differen ...... th high-responding inhibitors.
@ast
Economic modelling of differen ...... th high-responding inhibitors.
@en
prefLabel
Economic modelling of differen ...... th high-responding inhibitors.
@ast
Economic modelling of differen ...... th high-responding inhibitors.
@en
P2093
P2860
P1433
P1476
Economic modelling of differen ...... th high-responding inhibitors.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2516.2003.00783.X
P577
2003-07-01T00:00:00Z